BioCryst Pharmaceuticals
BCRX
BCRX
115 hedge funds and large institutions have $283M invested in BioCryst Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 35 reducing their positions, and 17 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
6% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 17
1.42% less ownership
Funds ownership: 90.83% → 89.41% (-1.4%)
25% less capital invested
Capital invested by funds: $380M → $283M (-$96.8M)
Holders
115
Holding in Top 10
3
Calls
$1.02M
Puts
$185K
Top Buyers
| 1 | +$9.34M | |
| 2 | +$7.16M | |
| 3 | +$4.66M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.93M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.39M |
Top Sellers
| 1 | -$10.1M | |
| 2 | -$5.48M | |
| 3 | -$5.11M | |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$4.75M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.79M |